Clinical Trial Update: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo [Phase 2]

View source ↗

Summary

A Phase 2b dose-ranging study is evaluating the efficacy and safety of GIA632 for non-segmental vitiligo, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• GIA632

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-segmental Vitiligo | Phase 2 | Status: RECRUITING